Distribution of AE clinical observations resulting from a platelet transfusion.

<p><b>A</b>. All PCs. <b>B</b>. PCs delivered before 3 days. <b>C</b>. PCs delivered from 3 to 5 days. The data are shown as percentages. FNHTR, febrile non-hemolytic transfusion reaction (fever or chill); AATRs, atypical allergic transfusion reactions (erythematous rash, urticaria, and/or pruritus or more severe reactions with angioedema); hemodynamic trouble (HT), excluding ALI (and TRALI), TACO, myocardial infarctions, and pulmonary embolism; combined ATRs, ATRs with two or more associated manifestations. We did not analyze any case with bronchospasm or anaphylaxis.</p

Pearson correlation matrix of 16 soluble factors in 65 ATRs supernatants.

<p>The bold values were different from 0 at a significance level of α = 0.05.</p

Discriminatory ability of soluble factors to classify PCs as belonging to either the adverse effect or control group.

<p>All AUCs with a p-value of <0.0001 (z-test) were considered different from 0.5.</p

Parameters of platelet donors and storage time of the platelet concentrates.

a<p>The data are shown as percentages.</p

Examples of areas under the ROC curves.

<p><b>A</b>. sCD40L; <b>B</b>. MIP-1α; <b>C</b>. IL13; <b>D</b>. BCA-1.</p

Concentrations of 17 soluble factors in the supernatants from 65 ATRs PCs and 59 control PCs.

<p>The data are adjusted to pg/10⁹ platelets and expressed as the mean ± SEM. <b>A</b>. Factors that did not display any difference between the control and AE samples. <b>B</b>. Factors that had a concentration in the AE samples that was significantly higher than in the control samples or that were detected only in the ATR samples. <b>C</b>. Factors that were not detected in the controls, regardless of the amounts in the ATR samples (concentrations in the control and ATR samples were compared using two-tailed Student's t test, *p<0.05).</p

Decision tree.

<p><b>A</b>. Assays without IL13 (among 16 assays, the success rate of the sCD40L model was the highest, 78%); <b>B</b>. Assays with IL13 (among 17 assays, the success rate of the IL13 model was the highest, 82%).</p

Release of soluble factors during platelet storage for 5 days.

<p>The data are adjusted to pg/10⁹ platelets and expressed as the mean ± SEM. <b>A</b>. Factors that increased over 5 days of storage in only the control samples. <b>B</b>. Factors that were constantly secreted with almost equivalent amounts between days 1 and 5 in the supernatants from “pathogenic” PCs but that were not detectable at any time between days 1 and 5 in the control samples. <b>C</b>. Factors with invariable trace amounts—between days 1 and 5 in the control PC supernatants and with elevated concentrations, but only on days 4 and 5, in the “pathogenic” PC supernatants. <b>D</b>. Factors that were elevated in both the control and pathogenic supernatants, although with significant variations between the control and ATR samples (concentrations of the soluble factors on days 2–5 vs. day 1 in the same group were compared using ANOVA, *p<0.05).</p